RxDoctor Payments DataLook up a doctor →

Anthony Esposito, MD

Neurology · Anniston, ALNPI 1083655187

Payments from drug & device makers

$80,994in general payments, 2019–2025

Across 1,080 payments — averaging $74.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59K
  • SK Life Science, Inc.$3K
  • EMD Serono, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Novartis$1K
  • Biogen$1K
  • plus $11K from 51 others

What the payments were for

  • Consulting fees$5,5757%
  • Speaking & faculty fees$54,56967%
  • Travel & lodging$2,1943%
  • Food & beverage$18,43423%
  • Education$2230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)237$59,128
SK Life Science, Inc.35$3,210
EMD Serono, Inc.40$2,692
Teva Pharmaceuticals USA, Inc.44$2,665
Novartis90$1,418
Biogen94$1,221
UCB, Inc.56$953
CSL Behring19$942
Lundbeck LLC32$649
Supernus Pharmaceuticals, Inc.33$602
Lilly USA, LLC28$522
Amgen(2 entities)26$429
Neurelis, Inc.21$379
Argenx US, Inc.16$377
Neurocrine Biosciences, Inc.19$366
Bristol Myers Squibb9$364
Upsher-smith Laboratories LLC23$353
Sunovion Pharmaceuticals Inc.22$340
Eisai Inc.20$336
Pfizer13$289
MDD US Operations, LLC18$286
Galt Pharmaceuticals, LLC1$282
Biohaven Pharmaceuticals, Inc.19$256
Acadia Pharmaceuticals Inc15$241
Catalyst Pharmaceuticals, Inc.12$223
Sanofi13$213
Amneal Pharmaceuticals LLC12$206
AstraZeneca9$195
Acorda Therapeutics, Inc11$184
Biohaven Pharmaceutical Holding Company Ltd.11$169
Adamas Pharmaceuticals, Inc.8$118
TG Therapeutics, Inc.6$113
Scilex Pharmaceuticals Inc.7$108
ANI Pharmaceuticals, Inc.5$101
Impel Pharmaceuticals Inc.6$97
Stryker1$95
Kyowa Kirin, Inc.6$89
Johnson & Johnson(2 entities)5$87
Jazz Pharmaceuticals Inc.4$83
Sumitomo Pharma America, Inc.4$80
Avion Pharmaceuticals4$75
GE HealthCare2$71
Avanir Pharmaceuticals, Inc.3$52
Assertio Therapeutics, Inc.4$52
Merck2$38
E.r. Squibb & Sons, L.L.C.2$29
Collegium Pharmaceutical, Inc.2$28
Otsuka America Pharmaceutical, Inc.2$27
Amylyx Pharmaceuticals, Inc.1$21
Grifols USA, LLC1$19
Idorsia Pharmaceuticals US Inc1$19
Ipsen Biopharmaceuticals, Inc1$18
Livanova USA, Inc.1$18
Genentech USA, Inc.1$17
Alnylam Pharmaceuticals Inc.1$16
Boston Scientific1$16
Ceribell, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,994 in reported general payments places this provider in the 80th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$74,570
Medicare patients
381
Services billed
3,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a43$359,573
AustedoDeutetrabenazine37$284,989
BetaseronInterferon Beta-1b17$190,959
Avonex (4 Pack)Interferon Beta-1a13$137,014
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$132,772
Austedo XrDeutetrabenazine26$122,772
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5019$106,490
Nurtec OdtRimegepant Sulfate63$94,522
QuliptaAtogepant72$80,181
TopamaxTopiramate32$57,037
NuplazidPimavanserin Tartrate12$56,823
Aimovig AutoinjectorErenumab-Aooe63$53,928
UbrelvyUbrogepant44$51,921
VimpatLacosamide32$48,510
XcopriCenobamate37$45,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$2,665$407,76163 claims
BiogenAvonex (4 Pack)$1,221$137,01413 claims
AbbVieQulipta, Ubrelvy$59,128$132,102116 claims
PfizerNurtec Odt$289$94,52263 claims
UCB, Inc.Vimpat, Briviact$953$68,17444 claims
Acadia Pharmaceuticals IncNuplazid$241$56,82312 claims
SK Life Science, Inc.Xcopri$3,210$45,54837 claims
Collegium Pharmaceutical, Inc.Xtampza Er$28$42,55024 claims
Sunovion Pharmaceuticals Inc.Aptiom$340$36,32614 claims
Eisai Inc.Fycompa$336$20,35616 claims
Neurelis, Inc.Valtoco$379$14,12016 claims
MerckBelsomra$38$8,00718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 neurology providers in Alabama.

Other neurology in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →